34717775|t|Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
34717775|a|The clinicopathological heterogeneity in Lewy-body diseases (LBD) highlights the need for pathology-driven biomarkers in-vivo. Misfolded alpha-synuclein (alpha-Syn) is a lead candidate based on its crucial role in disease pathophysiology. Real-time quaking-induced conversion (RT-QuIC) analysis of CSF has recently shown high sensitivity and specificity for the detection of misfolded alpha-Syn in patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). In this study we performed the CSF RT-QuIC assay in 236 PD and 49 DLB patients enriched for different genetic forms with mutations in GBA, parkin, PINK1, DJ1, and LRRK2. A subgroup of 100 PD patients was also analysed longitudinally. We correlated kinetic seeding parameters of RT-QuIC with genetic status and CSF protein levels of molecular pathways linked to alpha-Syn proteostasis. Overall, 85% of PD and 86% of DLB patients showed positive RT-QuIC alpha-Syn seeding activity. Seeding profiles were significantly associated with mutation status across the spectrum of genetic LBD. In PD patients, we detected positive alpha-Syn seeding in 93% of patients carrying severe GBA mutations, in 78% with LRRK2 mutations, in 59% carrying heterozygous mutations in recessive genes, and in none of those with bi-allelic mutations in recessive genes. Among PD patients, those with severe GBA mutations showed the highest seeding activity based on RT-QuIC kinetic parameters and the highest proportion of samples with 4 out of 4 positive replicates. In DLB patients, 100% with GBA mutations showed positive alpha-Syn seeding compared to 79% of wildtype DLB. Moreover, we found an association between alpha-Syn seeding activity and reduced CSF levels of proteins linked to alpha-Syn proteostasis, specifically lysosome-associated membrane glycoprotein 2 and neurosecretory protein VGF.These findings highlight the value of alpha-Syn seeding activity as an in-vivo marker of Lewy-body pathology and support its use for patient stratification in clinical trials targeting alpha-Syn.
34717775	24	39	alpha-synuclein	Gene	6622
34717775	79	98	Parkinson's disease	Disease	MESH:D010300
34717775	103	128	dementia with Lewy bodies	Disease	MESH:D020961
34717775	171	189	Lewy-body diseases	Disease	MESH:D020961
34717775	191	194	LBD	Disease	MESH:D020961
34717775	267	282	alpha-synuclein	Gene	6622
34717775	284	293	alpha-Syn	Gene	6622
34717775	515	524	alpha-Syn	Gene	6622
34717775	528	536	patients	Species	9606
34717775	542	561	Parkinson's disease	Disease	MESH:D010300
34717775	563	565	PD	Disease	MESH:D010300
34717775	571	596	dementia with Lewy bodies	Disease	MESH:D020961
34717775	598	601	DLB	Disease	MESH:D020961
34717775	660	662	PD	Disease	MESH:D010300
34717775	670	673	DLB	Disease	MESH:D020961
34717775	674	682	patients	Species	9606
34717775	738	741	GBA	Gene	2629
34717775	743	749	parkin	Gene	5071
34717775	751	756	PINK1	Gene	65018
34717775	758	761	DJ1	Gene	11315
34717775	767	772	LRRK2	Gene	120892
34717775	792	794	PD	Disease	MESH:D010300
34717775	795	803	patients	Species	9606
34717775	965	974	alpha-Syn	Gene	6622
34717775	1005	1007	PD	Disease	MESH:D010300
34717775	1019	1022	DLB	Disease	MESH:D020961
34717775	1023	1031	patients	Species	9606
34717775	1056	1065	alpha-Syn	Gene	6622
34717775	1183	1186	LBD	Disease	MESH:D020961
34717775	1191	1193	PD	Disease	MESH:D010300
34717775	1194	1202	patients	Species	9606
34717775	1225	1234	alpha-Syn	Gene	6622
34717775	1253	1261	patients	Species	9606
34717775	1278	1281	GBA	Gene	2629
34717775	1305	1310	LRRK2	Gene	120892
34717775	1454	1456	PD	Disease	MESH:D010300
34717775	1457	1465	patients	Species	9606
34717775	1485	1488	GBA	Gene	2629
34717775	1649	1652	DLB	Disease	MESH:D020961
34717775	1653	1661	patients	Species	9606
34717775	1673	1676	GBA	Gene	2629
34717775	1703	1712	alpha-Syn	Gene	6622
34717775	1749	1752	DLB	Disease	MESH:D020961
34717775	1796	1805	alpha-Syn	Gene	6622
34717775	1868	1877	alpha-Syn	Gene	6622
34717775	1905	1948	lysosome-associated membrane glycoprotein 2	Gene	3920
34717775	1976	1985	VGF.These	Gene	7425
34717775	2018	2027	alpha-Syn	Gene	6622
34717775	2069	2088	Lewy-body pathology	Disease	MESH:D020961
34717775	2113	2120	patient	Species	9606
34717775	2165	2174	alpha-Syn	Gene	6622
34717775	Association	120892	6622
34717775	Association	MESH:D010300	120892
34717775	Association	MESH:D010300	6622
34717775	Association	MESH:D020961	6622
34717775	Association	2629	6622
34717775	Association	MESH:D010300	2629

